Further Insights into Mechanism of Action of Icosapent Ethyl and Its Unique Form of Eicosapentaenoic Acid (EPA) Presented at the European Atherosclerosis Society (EAS) Congress 2021GlobeNewsWire • 06/02/21
Amarin Corporation's (AMRN) CEO John Thero on Jefferies Virtual Healthcare Conference - TranscriptSeeking Alpha • 06/02/21
Amarin Highlights Multiple Scientific Findings for VASCEPA® (Icosapent Ethyl) and Its Unique Active Ingredient at the American College of Cardiology's 70th Annual Scientific SessionGlobeNewsWire • 05/17/21
REDUCE-IT® Heart Failure Analyses by VASCEPA® (Icosapent Ethyl)-Driven Serum Eicosapentaenoic Acid (EPA) Levels Suggest Potential Benefit in New Heart Failure in Studied At-Risk Patients as Presented at the American College of Cardiology's 70th Annual SciGlobeNewsWire • 05/15/21
Clinical Data and Other Research Results Regarding VASCEPA® (Icosapent Ethyl) and Its Unique Active Ingredient to Be Presented at the American College of Cardiology's 70th Annual Scientific SessionGlobeNewsWire • 05/04/21
Amarin Corporation PLC (AMRN) CEO John Thero on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 04/29/21
Amarin Reports First Quarter 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 04/29/21
Amarin Announces Planned Retirement of Joseph T. Kennedy, EVP, General CounselGlobeNewsWire • 04/29/21
Amarin Receives Great Britain Marketing Authorization for VAZKEPA from the Medicines and Healthcare Products Regulatory Agency (MHRA) 1,2GlobeNewsWire • 04/22/21
Amarin to Report First Quarter Results and Host Conference Call on April 29, 2021GlobeNewsWire • 04/20/21
VASCEPA® (Icosapent Ethyl) Reported to Impact Vulnerable Coronary Plaque Features in New Analyses of EVAPORATE Study Presented as Late-Breaking Science at ESC Preventive Cardiology 2021GlobeNewsWire • 04/17/21
With Their European Approval In Hand, Amarin Signals A Strategic Shift With A New CEOSeeking Alpha • 04/13/21
Amarin Commences Commercial Initiatives for VAZKEPA in European Union Following Recent Regulatory Approval for Cardiovascular Risk Reduction IndicationGlobeNewsWire • 04/06/21